We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$424M
AUM Growth
+$63.8M
Cap. Flow
+$65.2M
Cap. Flow %
15.39%
Top 10 Hldgs %
48.45%
Holding
91
New
14
Increased
28
Reduced
11
Closed
21
Avg Time Held Equity + Options
3.6 quarters
Top 10 Avg Time Held Equity + Options
1.3 quarters
Top 20 Avg Time Held Equity + Options
1.6 quarters
Avg Time Held Equity only
3.8 quarters
Top 10 Avg Time Held Equity only
1.3 quarters
Top 20 Avg Time Held Equity only
1.9 quarters

Top Buys

Rank Stock Value
1
NUVL icon
Nuvalent
NUVL
+$21.9M
2
ERAS icon
Erasca
ERAS
+$16.4M
3
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$10.9M
4
URGN icon
UroGen Pharma
URGN
+$8.44M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$7.74M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$7.96M
2
ALPN icon
Alpine Immune Sciences Inc
ALPN
+$7.89M
3
SLDB icon
Solid Biosciences
SLDB
+$7.63M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.98M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$5.83M

Sector Composition

Rank Sector Weight
1 Healthcare 95.56%
2 Miscellaneous 4.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRUS icon
1
DELISTED
Merus
MRUS
$36.9M 8.71%
623,628
+57,341
+10% +$2.78M
2021 Q1
13 quarters
NUVL icon
2
DELISTED
Nuvalent
NUVL
$35.3M 8.33%
465,710
+307,960
+195% +$21.9M
2023 Q4
2 quarters
RNAM
3
DELISTED
Avidity Biosciences
RNAM
$21.1M 4.99%
517,734
+28,431
+6% +$816K
2024 Q1
1 quarter
URGN icon
4
UroGen Pharma
URGN
$1.87B
$18.5M 4.36%
1,102,000
+593,413
+117% +$8.44M
2023 Q3
3 quarters
ERAS icon
5
Erasca
ERAS
$5.23B
$18.4M 4.35%
7,816,926
+7,593,081
+3,392% +$16.4M
2024 Q1
1 quarter
INSM icon
6
CALL
Insmed
INSM
$21B
$16.8M 3.95%
+250,000
New +$9.7M
2024 Q2
0 quarters
MORF icon
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$16.6M 3.91%
486,306
+2,334
+0.5% +$69.1K
2020 Q4
14 quarters
AKRO icon
8
DELISTED
Akero Therapeutics
AKRO
$14.7M 3.46%
625,087
+225,138
+56% +$4.81M
2022 Q2
8 quarters
CLDX icon
9
Celldex Therapeutics
CLDX
$2.23B
$13.9M 3.27%
374,910
+75,594
+25% +$2.85M
2023 Q4
2 quarters
ITCI icon
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.2M 3.11%
192,345
+157,538
+453% +$10.9M
2020 Q4
14 quarters
PSTX icon
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$10.5M 2.49%
3,607,999
+11,523
+0.3% +$31.5K
2021 Q4
10 quarters
COGT icon
12
Cogent Biosciences
COGT
$4.98B
$10.2M 2.4%
1,206,214
+169,547
+16% +$1.29M
2020 Q4
14 quarters
INSM icon
13
Insmed
INSM
$21B
$9.38M 2.21%
140,000
+26,384
+23% +$1.02M
2020 Q4
14 quarters
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$30.2B
$8.75M 2.06%
+36,000
New +$5.68M
2024 Q2
0 quarters
ELUT icon
15
Elutia
ELUT
$34.3M
$7.95M 1.88%
1,603,580
+1,525,000
+1,941% +$4.96M
2024 Q1
1 quarter
CRBP icon
16
Corbus Pharmaceuticals
CRBP
$90.7M
$7.81M 1.84%
172,492
+140,512
+439% +$5.91M
2024 Q1
1 quarter
ORIC icon
17
Oric Pharmaceuticals
ORIC
$1.21B
$7.61M 1.79%
1,075,812
-37,195
-3% -$333K
2022 Q2
8 quarters
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.24B
$7.6M 1.79%
+370,000
New +$7.74M
2024 Q2
0 quarters
RYTM icon
19
Rhythm Pharmaceuticals
RYTM
$6.02B
$7.58M 1.79%
184,662
+886
+0.5% +$35.4K
2023 Q2
4 quarters
CCCC icon
20
C4 Therapeutics
CCCC
$335M
$6.67M 1.57%
1,442,841
+6,910
+0.5% +$41.2K
2024 Q1
1 quarter
SRPT icon
21
Sarepta Therapeutics
SRPT
$1.76B
$6.64M 1.57%
+42,000
New +$5.4M
2024 Q2
0 quarters
KALV icon
22
DELISTED
KalVista Pharmaceuticals
KALV
$6.61M 1.56%
560,883
-300
-0.1% -$3.5K
2023 Q1
5 quarters
VCYT icon
23
Veracyte
VCYT
$3.52B
$6.12M 1.44%
282,248
+1,475
+0.5% +$31K
2021 Q1
13 quarters
ABVX icon
24
Abivax
ABVX
$7.79B
$6.03M 1.42%
455,800
+380,800
+508% +$5.45M
2024 Q1
1 quarter
OLMA icon
25
Olema Pharmaceuticals
OLMA
$614M
$5.92M 1.4%
546,863
+31,546
+6% +$342K
2023 Q2
4 quarters
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Silverarc Capital Management held 91 positions worth $424M, up 18% from $360M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $65.2M of net new capital in Q2 2024, opening 14 new positions and adding to 28 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Perspective Therapeutics, an estimated $7.96M trimmed.

  • Silverarc Capital Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.
  • Silverarc Capital Management added most to Nuvalent in Q2 2024, an estimated $21.9M increase.
  • Silverarc Capital Management's biggest Q2 2024 reduction was Perspective Therapeutics, cutting an estimated $7.96M.
  • Silverarc Capital Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $7.89M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $424M portfolio in Q2 2024.
  • Silverarc Capital Management opened 14 new positions and closed 21 in Q2 2024.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $424M.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.